Jeanmarie Guenot and Amphivena Therapeutics are currently working on a groundbreaking study to cure for Acute Myeloid Leukemia, or AML. Guenot is a Ph.D. with over twenty years experience in the pharmaceutical and biotechnology industry. Amphivena is a new company that was able to raise fourteen million dollars for its start. The drug currently going through the FDA approved trials is AMV-564.
AML is the most common form of adult leukaemia and can move through a person quickly. While it is considered extremely rare, the cure could lead to understanding other cancers. One of the ways to contract AML is the treatment to combat other cancers. Chemotherapy and radiation can cause the cancer by mutating the chromosomes in certain leukemic cells.
AMV-564 is an antibody that that recruits T-cells to eliminate the cancer cells that express CD33, which is a receptor that common in AML. The receptor is also common to other blood tumors. Such an antigen type treatment is considered promising. The treatment itself is part of a long pursued path to find a cure for this fast acting cancer.
Jeanmarie Guenot is the President and CEO of Amphivena. She also is part of the group of patent holders for three of the three main components of AMV-564. Prior to Amphivena, she built and ran SKS Ocular, a company that focused on glaucoma, macular degeneration, and ocular inflammation. She earned her doctorate at the University of California, San Francisco and an MBA from the prestigious Wharton School at the University of Pennsylvania. She has primarily worked in the field of cancer research, focusing on physical and medicinal chemistry.
Amphivena Therapeutics is a developer of treatments for diseases, not just cancer. They are developing drugs that utilize a patient’s immune system to fight the diseases themselves. They are based out of San Francisco after being founded in 2012. The company itself is extremely small and is still privately owned.
Learn more about Jeanmarie Guenot, and her new partnership with Takeda.